{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:33:17Z","timestamp":1793406797486,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>Inflammatory myofibroblastic tumor (IMT) can occur in a number of anatomic sites, including the uterus. Like its soft tissue counterpart, uterine IMT frequently expresses ALK and harbors <jats:italic toggle=\"yes\">ALK<\/jats:italic> genetic rearrangements. The aim of this study is to fully characterize the genetic fusions that occur in uterine IMT. We studied 11 uterine IMTs with typical histology and 8 uterine myxoid smooth muscle tumors (5 leiomyomas, 1 smooth muscle tumor of uncertain malignant potential, and 2 leiomyosarcomas) in which the differential of IMT was considered, using a RNA-sequencing\u2013based fusion assay to detect genetic fusions involving <jats:italic toggle=\"yes\">ALK<\/jats:italic>, <jats:italic toggle=\"yes\">ROS1<\/jats:italic>, <jats:italic toggle=\"yes\">RET<\/jats:italic>, <jats:italic toggle=\"yes\">NTRK1\/3<\/jats:italic>, and other genes. ALK was expressed in 10 of 11 IMTs and 1 tumor initially categorized as a myxoid leiomyoma (granular cytoplasmic staining with paranuclear accentuation). Fusion transcripts involving <jats:italic toggle=\"yes\">ALK<\/jats:italic> were identified in 9 of 10 ALK immunopositive IMTs, with 3 harboring <jats:italic toggle=\"yes\">IGFBP5-ALK<\/jats:italic>, 3 harboring <jats:italic toggle=\"yes\">THBS1-ALK<\/jats:italic>, 2 harboring <jats:italic toggle=\"yes\">FN1-ALK<\/jats:italic>, and 1 harboring <jats:italic toggle=\"yes\">TIMP3-ALK<\/jats:italic>. Among the smooth muscle tumors, <jats:italic toggle=\"yes\">IGFBP5-ALK<\/jats:italic> fusion transcript was identified in only 1 ALK immunopositive case. Further review revealed that although a diagnosis of IMT was considered for the ALK immunopositive myxoid leiomyoma, this diagnosis was not initially rendered only because fluorescence in situ hybridization analysis was interpreted as negative for <jats:italic toggle=\"yes\">ALK<\/jats:italic> genetic rearrangement; this case is best reclassified as an IMT. Notably, all the <jats:italic toggle=\"yes\">ALK<\/jats:italic> fusions identified in our study included the transmembrane domain-encoding exon 19 of <jats:italic toggle=\"yes\">ALK<\/jats:italic>. Our findings confirm the high frequency of <jats:italic toggle=\"yes\">ALK<\/jats:italic> fusions in uterine IMT, with an enrichment of novel 5\u2032 <jats:italic toggle=\"yes\">ALK<\/jats:italic> fusion partners (<jats:italic toggle=\"yes\">IGFBP5<\/jats:italic>, <jats:italic toggle=\"yes\">THBS1<\/jats:italic>, and <jats:italic toggle=\"yes\">TIMP3<\/jats:italic>) and exon 19-containing <jats:italic toggle=\"yes\">ALK<\/jats:italic> fusion. Given that <jats:italic toggle=\"yes\">IGFBP5<\/jats:italic> and <jats:italic toggle=\"yes\">FN1<\/jats:italic> are both situated on the same chromosome as <jats:italic toggle=\"yes\">ALK<\/jats:italic>, fluorescence in situ hybridization analysis for <jats:italic toggle=\"yes\">ALK<\/jats:italic> rearrangement may not be reliable and a negative result should not exclude a diagnosis of uterine IMT if the histologic features and ALK immunostaining findings are supportive.<\/jats:p>","DOI":"10.1097\/pas.0000000000000801","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T15:00:49Z","timestamp":1491577249000},"page":"773-780","source":"Crossref","is-referenced-by-count":139,"title":["Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1"],"prefix":"10.1097","volume":"41","author":[{"given":"Josh D.","family":"Haimes","sequence":"first","affiliation":[{"name":"ArcherDX Inc., Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.R.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Histopathology, King Edward Memorial Hospital, Perth, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Kudlow","sequence":"additional","affiliation":[{"name":"ArcherDX Inc., Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady P.","family":"Culver","sequence":"additional","affiliation":[{"name":"ArcherDX Inc., Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Koay","sequence":"additional","affiliation":[{"name":"Department of Histopathology, King Edward Memorial Hospital, Perth, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Whitehouse","sequence":"additional","affiliation":[{"name":"Sullivan Nicolaides Pathology, Brisbane, Qld, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cope","sequence":"additional","affiliation":[{"name":"Department of Pathology, Royal Devon and Exeter Hospital, Exeter"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Chieh","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Pathology, British Columbia Cancer Agency and Vancouver General Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Glenn","family":"McCluggage","sequence":"additional","affiliation":[{"name":"Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB"},{"name":"Department of Pathology, British Columbia Cancer Agency and Vancouver General Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9440(10)61711-7","article-title":"Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor","volume":"159","author":"Bridge","year":"2001","journal-title":"Am J Pathol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","article-title":"TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors","volume":"157","author":"Lawrence","year":"2000","journal-title":"Am J Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/gcc.10177","article-title":"Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor","volume":"37","author":"Ma","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1067\/S0002-9378(03)00208-4","article-title":"Inflammatory myoblastic tumor of the uterus and interleukin-6","volume":"189","author":"Azuno","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2013.48.8304","article-title":"Uterine inflammatory myofibroblastic tumor in a 10-year-old girl presenting as polypoid mass","volume":"33","author":"Fraggetta","year":"2015","journal-title":"J Clin Oncol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gynor.2013.07.007","article-title":"Extrauterine inflammatory myofibroblastic tumor: a case report","volume":"6","author":"Kushnir","year":"2013","journal-title":"Gynecol Oncol Case Rep"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejogrb.2011.02.016","article-title":"Hysteroscopic excision of inflammatory myofibroblastic tumor of the uterus: a case report and brief review","volume":"157","author":"Olgan","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/PAS.0000000000000330","article-title":"Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course","volume":"39","author":"Parra-Herran","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAS.0000000000000593","article-title":"Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms","volume":"40","author":"Parra-Herran","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/01.pas.0000172189.02424.91","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors","volume":"29","author":"Rabban","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1440-1827.2006.02018.x","article-title":"Inflammatory myofibroblastic tumor of the uterus with prominent myxoid change","volume":"56","author":"Shintaku","year":"2006","journal-title":"Pathol Int"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-015-0160-2","article-title":"STUMP un\u201cstumped\u201d: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion","volume":"8","author":"Subbiah","year":"2015","journal-title":"J Hematol Oncol"},{"key":"R16-20230922","article-title":"Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing","author":"Murphy","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK","volume":"35","author":"Marino-Enriquez","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R18-20230922","first-page":"240","article-title":"Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer","volume":"4","author":"McLeer-Florin","year":"2012","journal-title":"J Thorac Dis"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1002\/cncr.27411","article-title":"Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer","volume":"118","author":"Camidge","year":"2012","journal-title":"Cancer"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"e57901","DOI":"10.1371\/journal.pone.0057901","article-title":"An integrative genomic and transcriptomic analysis reveals potential targets associated with cell proliferation in uterine leiomyomas","volume":"8","author":"Cirilo","year":"2013","journal-title":"PLoS One"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"23462","DOI":"10.1074\/jbc.M002208200","article-title":"Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit","volume":"275","author":"Schedlich","year":"2000","journal-title":"J Biol Chem"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.fertnstert.2004.09.035","article-title":"Expression and regulation of thrombospondin-1 by human endometrial stromal cells","volume":"83","author":"Kawano","year":"2005","journal-title":"Fertil Steril"},{"key":"R23-20230922","first-page":"1495","article-title":"Expression of matricellular proteins in human uterine leiomyomas and normal myometrium","volume":"27","author":"Bogusiewicz","year":"2012","journal-title":"Histol Histopathol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/JME-11-0004","article-title":"Anaplastic lymphoma kinase in human cancer","volume":"47","author":"Barreca","year":"2011","journal-title":"J Mol Endocrinol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MOH.0b013e3283623c07","article-title":"Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma","volume":"20","author":"Tabbo","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/JTO.0b013e3182598af3","article-title":"A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK","volume":"7","author":"Penzel","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm0311-290","article-title":"Hunting ALK to feed targeted cancer therapy","volume":"17","author":"Wellstein","year":"2011","journal-title":"Nat Med"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/modpathol.2016.129","article-title":"Recurrent fusion of the genes FN1 and ALK in gastrointestinal leiomyomas","volume":"29","author":"Panagopoulos","year":"2016","journal-title":"Mod Pathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/pbc.25424","article-title":"FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor","volume":"62","author":"Ouchi","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1158\/0008-5472.CAN-11-3931","article-title":"Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer","volume":"72","author":"Ren","year":"2012","journal-title":"Cancer Res"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J Clin Oncol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.jtho.2016.07.008","article-title":"A case of lung adenocarcinoma resistant to crizotinib harboring a novel EML4-ALK variant, exon 6 of EML4 fused to exon 18 of ALK","volume":"11","author":"Anai","year":"2016","journal-title":"J Thorac Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201706000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:25:47Z","timestamp":1695421547000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201706000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000801","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}